ArticleDrug safety2026
The Value of Time-to-Onset for Signal Validation: Experience from the Reporting of COVID-19 Vaccines and Glomerular Diseases in VigiBase.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdverse event reports of glomerular diseases (GDs) following coronavirus disease 2019 (COVID-19) vaccination collected nationally have been shared to VigiBase, the global database of adverse event reports for medicines and vaccines. From literature reports, different GDs following COVID-19 vaccination have different time-to-onsets (TTOs), highlighting the potential value of TTO in suggesting underlying disease mechanisms and supporting its relevance in signal validation prior to in-depth signal assessment.
objectiveThe aim of this study was to characterise the TTO in reports of GDs in association with COVID-19 vaccines inVigiBase. The analysis focuses on exploring the value of TTO for signal validation, an early step preceding signal assessment.
methodsReports for four different GDs in association with COVID-19 vaccines were extracted from VigiBase on 3 April, 2023. The reports were de-duplicated and TTO information was manually verified. Demographics and clinical characteristics were summarised per GD. The median TTO was compared between GDs and by disease status (relapse and new onset cases) within each GD.
resultsIn the extracted data, 245 unique cases shared to VigiBase and containing information about both TTO and disease status for the four selected GDs in association with COVID-19 vaccines were identified. Reports for IgA nephropathy represented the majority (49%). Most of the GD cases concerned messenger RNA COVID-19 vaccines (84%) and most occurred following the second dose (54%). Differences in median TTO between the four GDs as well as between disease status within the GDs were observed. However, except between IgA nephropathy and the other three GDs, these differences were not statistically significant.
conclusionsThis study explores TTO differences for four different GDs following COVID-19 vaccination, taking new onset or relapse cases into account. The study demonstrates how review and characterisation of TTO data can complement traditional disproportionality analysis in the early stage of signal validation. The presented hypothesis will require further investigation.
Identifiers
42821030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.